Promega Preview (UK and Ireland) - January 2025
Promega UK
We're the UK Promega life sciences team, sharing technical tips, our event info, science news, articles and blog posts.
Welcome to the first issue of 2025!
Supporting Heart Health with Wessex Heartbeat
This month we were delighted to welcome Mark Ind and Professor Nick Curzen from Wessex Heartbeat, a regional charity dedicated to supporting patients with congenital and cardiovascular diseases, as well as their families.
To learn more about Wessex Heartbeat and how Promega UK is proud to support their mission, visit our blog.
NEW Product | Lumit??dsRNA Detection Assay
Do you need to detect and quantify dsRNA? If so our latest Lumit? assay could be just what you’re looking for. With no cross reactivity to ssRNA or DNA, this sensitive assay allows you to quantitatively measure dsRNA independently of size or sequence (≥30bp). The simple workflow doesn’t require wash steps and doesn’t rely on antibodies for detection of dsRNA.
New Product | Quantify Target Cell Killing with Confidence
HiBiT Target Cell Killing (TCK) Bioassays provide a cutting-edge, highly specific method for accurately measuring the activity of biologic drugs where target cell lysis is a key mechanism of action. With applications across a broad spectrum of next-generation biologics, including CAR-T cells, bispecific antibodies and monoclonal antibodies, these assays deliver quantitative readouts with unmatched precision and flexibility. Their scalable workflow supports drug development from early discovery through to commercial lot release.
Raji, Ramos and H929 HiBiT Target Cells are now available in the catalogue, with even more TCK target and effector cell lines available in Early Access.
领英推荐
Find Promega UK at...
Promega Research Shows Potential of Selective Degrader Against Paediatric Cancer Cell Lines
Promega research?published this month in?Nature Communications?demonstrates a new potential approach for managing multiple myeloma and other haematological cancers. The molecule, called SJ3149, demonstrates potent anti-proliferative activity in a variety of human cancer cell lines through selective degradation of the cancer-causing protein CK1α. The authors suggest that this degrader shows great promise for broad-spectrum anti-cancer applications.
At Promega, we love to talk science. Setting your communication preferences prevents inbox clutter by joining conversations about topics relevant to your research.
Log in or create a free account to update and manage your communication preferences - we also give away one hamper per quarter (GB only) to those who update their preferences.
Emerging Technologies Project Manager at Promega Corporation
1 个月Very excited about the new product launches- the Lumit dsRNA kit has already generated a lot of interest in the RNA therapy space and being able to accurately measure target-specific death is so important for mechanism-of-action studies for advanced therapies. Very much looking forward to working with scientists wanting to bring these assays in house!
Good luck to the entire team!